Alpha- Antitrypsin Deficiency, also called as AAT is a genetic disease that causes serious lung diseases that leads to difficulty in breathing. The disease might further spread to weaken the liver which would lead to jaundice. No cure has been discovered so far but with effective treatment, AAT can be kept in control without causing major respiratory difficulties. This disease is causes due to inability of the liver to produce a protein called Alpha- 1 antitrypsin in adequate quantities. Without this protein, irritants can easily attack the lungs at a faster rate. Symptoms are hard to be detected until in 20s or 30s when they slowly start surfacing. For a few people, AAT can lead to chronic bronchitis and even chronic pulmonary obstructive disease. Many affected with AAT often carry inhalers to ease their breathing just like in asthma. However, no two cases of AAT are alike.
Neutrophil elastase (NE) is capable of degrading a variety of structural proteins of the extracellular matrix. Excessive NE activity have been detected in various lung diseases, including bronchitis, pulmonary obstructive diseases. Endogenous human NE is mostly neutralised by AAT. Congenital deficiency of AAT leads to emphysema which can be treated with therapeutic AAT. Of recently, many synthetic and recombinant elastase inhibitors have been identified and are in the stage of development for clinical and preclinical purposes.
Pipeline Review is an online portal that provides R&D new and online shop for reports about research & development in the biopharmaceutical industry. Ken Research’s Alpha- Antitrypsin Deficiency – Pipeline Review, H2 2018 gives a snapshot of the therapeutic landscape of the disorder. The report covers therapeutic reviews based on their companies and research institutions based on their information derived from industry- specific sources. It provides descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The companies involved in therapeutic development in Alpha- Antitrypsin Deficiency are Adverum Biotechnologies Inc, Alnylam Pharmaceuticals Inc, Applied Genetic Technologies Corp, Arrowhead Pharmaceuticals Inc, AstraZeneca Plc, Carolus Therapeutics Inc, Editas Medicine Inc, Grifols SA, Inhibrx LP, Intellia Therapeutics Inc, International Stem Cell Corp, Kamada Ltd, Octapharma AG, OncBioMune Pharmaceuticals Inc, PlantForm Corp, Promethera Biosciences SA, ProMetic Life Sciences Inc, rEVO Biologics Inc, Santhera Pharmaceuticals Holding AG, Therapure Biopharma Inc and Z Factor Ltd. The report will help in procuring important information on competitors and their analysis to formulate R&D strategies to develop tactical initiatives in the target demographic.
For more information, click on the link below:
Ankur Gupta, Head Marketing & Communications